BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Long (1Y)
IDFC initiates Aurobindo Pharma with outperform
Aurobindo is now comparable with large-cap peers. Company has superior execution track record in the recent past. Aurobindo's valuation is at 25-30 per cent discount to large-cap peers. The company will give sustained delivery momentum. Large M&A transaction is a key risk to our re-rating thesis.